Genomic Health Highlights Secondary Analysis Of TAILORx Results Published Today In NEJM, Affirms Unique Ability of Oncotype DX Breast Recurrence Score® to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
Benzinga Newsdesk